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Intestinal in￿ ammation is controlled by various
immunomodulating cells, interacting by molecu-
lar mediators. Neuropeptides, released by enteric
nerve cells and neuroendocrine mucosa cells, are
able to affect several aspects of the general and
intestinal immune system, with both pro- as well
as anti-in￿ ammatory activities. In in￿ ammatory
bowel disease (IBD) there is both morphological
as well as experimental evidence for involvement
of neuropeptides in the pathogenesis. Somatosta-
tin is the main inhibitory peptide in in￿ amma-
tory processes, and its possible role in IBD is
discussed.
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Introduction
Ulcerative colitis and Crohn’s disease are both
characterized by chronic, relapsing intestinal
in￿ammation. The aetiology of both forms of
in￿ammatory bowel disease (IBD) is still un-
known, despite intensive research in two main
areas—abnormal regulation of the local immune
response and exogenous factors, including in-
fectious agents. The gastrointestinal immune
system protects the organism against toxins,
microorganisms and dietary antigens within the
gut lumen. It is generally assumed that luminal
stimuli presented to intestinal mucosa activate
intra-epithelial immunocytes resulting in release
of mediators of in￿ammation. In IBD an in￿am-
matory cascade is initiated and, due to insuf￿-
cient or inappropriate immune reactions,
intestinal damage results.1,2 The reasons for
inappropriate immune activation are unknown.
Central roles are currently ascribed in this
process to activated intestinal macrophages and
T -lymphocytes2 in combination with an imbal-
ance between pro- and contra-in￿ammatory T -
cells. 3- 5 Treatment of IBD is aimed at reducing
the production or action of mediators of in￿am-
mation.
Delicate interactions of intestinal mucosal
epithelium, smooth muscle cells, gut wall blood
vessel endothelium, immunocytes and enteric
nerve cells contribute to and regulate intestinal
in￿ammatory changes. These processes are
mediated by various chemical messengers, most
of which are produced by lymphocytes, granu-
locytes and macrophages. Recent studies on
aetiopathogenesis and treatment in IBD have
concentrated on these immunocyte products
which include cytokines, eicosanoids and adhe-
sion molecules. The contribution of other ele-
ments of the gastrointestinal immunological
defence system to chronic intestinal in￿amma-
tion is less well known. A potentially interesting
area is the immunoregulatory role of enteric
nerves and neuroendocrine cells. Neuropep-
tides, like substance P (SP), somatostatin (SMS),
vasoactive intestinal peptide (VIP) and calcito-
nin gene related peptide (CGRP), are the
molecular mediators of neuroregulation of the
intestinal immune system, providing for inter-
actions between nervous system and immuno-
cytes. SMS is a key inhibiting factor of many
biological processes. In this review the role of
SMS as neuroimmune modulator in IBD will be
highlighted, together with its possible future
use in the treatment of IBD.
Neuroin¯ ammation,
Neuropeptides and Intestinal
In¯ ammation
The concept of neuroimmune interaction is in
part derived from older clinical observation that
in￿ammatory processes are in￿uenced by emo-
tional or physical stress. The immune system is
subject to central nervous control and Pavlovian
responses.6 Although IBD patients do not have
more emotional dif￿culties or psychosocial
stress compared with a normal population,
disease activity and response to therapy are
certainly in￿uenced by the state of mental well-
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and the intestinal immune system is probably
mediated by neuropeptides derived from en-
teric nerves and neuroendocrine cells.8- 11
Membrane-bound neuropeptide receptors are
found on several immunocytes, including T -
lymphocytes and monocytes.6,9,12- 16 Various
neuropeptides affect intestinal lymphocyte func-
tion and several cells of the intestinal immune
system also produce neuropeptides, suggesting
a local immunoregulatory task. 17- 20 Migration of
immunocytes into the intestinal mucosa is
affected by neuropeptides.21
In addition there are several morphological
arguments that suggest neuropeptide involve-
ment in intestinal mucosal immunity. Intestinal
mucosa contains SP, VIP and SMS immuno-
reactive nerve ￿bres and co-localization is
common.22,23 Neuropeptides show a speci￿c
distribution along the gut. Transmural distribu-
tion can be different for different neu-
ropeptides. 24- 27
The reported studies of neuropeptide
immunomodulation in the intestine need to be
interpreted with some caution. Receptor bind-
ing studies often show unexpected concentra-
tion relationships and depend strongly on local
conditions. 28- 34 Autoradiography is a semiquan-
titative approach and sampling error in taking
mucosal biopsies or loss of neuropeptide con-
taining cells by in￿ammatory damage, may
account for some of the confusing results.
Structural and species speci￿c neuropeptide
receptor heterogeneity may further complicate
comparison of results. 35- 38 Neuropeptides are
known to exert different effects at different
sites. For instance skin mast cells are suscept-
ible to SMS, whereas SMS does not induce
histamine release from intestinal mast cells.39
Neuropeptides may be pro- or anti-in￿amma-
tory. Generally, substance P (SP) has a pro-
in￿ammatory action. Macrophage interleukin-1
(IL-1) production and cytotoxicity is stimulated
by SP20,40 as is IL-1, TNFa and IL-6 release by
human monocytes.31 SP stimulates proliferation
of and immunoglobulin synthesis by lympho-
cytes from spleen, mesenteric lymph nodes and
Peyer’s patches.28 Moreover, in experimental
infection with Schistosom a mansoni SP in-
duces IFNc production by granuloma macro-
phages.41 However, a dose-dependent inhibition
of immunoglobulin production of murine intest-
inal granuloma derived B-cells has been des-
cribed.42 Some of these pro-in￿ammatory effects
of SP are opposed by SMS. SMS inhibits macro-
phage SP-induced IFNc release.41 SP-induced
chemotaxis of neutrophils can be completely
reversed by the SMS analogue octreotide.43
In mucosal lymphocytes from resected human
colon segments, DNA synthesis as measured by
3H-thymidine uptake, is inhibited by low con-
centrations of SMS, VIP , SP and bombesin.44 This
inhibition might be principally achieved by T -
cell suppression, as it is observed in lympho-
cytes that are stimulated by concanavalin A.
The maximum inhibitory effects are obtained
after 4 days of neuropeptide incubation.44 VIP
and SMS inhibit lymphocytic proliferation in a
dose-dependent fashion.17,28,29,45 The inhibitory
effects of VIP and SMS on these lymphocytes
are mediated by speci￿c receptors, not by
cytotoxicity.46- 48
VIP has both pro- and anti-in￿ammatory
effects on intestinal T -cells and macrophages,
inducing IL-5 release and inhibiting macrophage
adherence.49,50 T -cell cAMP increases on stimu-
lation by VIP , but proliferation is inhibited.38,51
However, reactivity of granuloma B-cells and
macrophages is not affected.38,42
Con￿icting results emerge from studies in IBD
patients. SP content of in￿amed colon is in-
creased, but there is a substantial overlap with
normal SP content.52,53 SP receptor upgrading is
observed in in￿amed areas of IBDcolon. 54- 57 SP
receptor expression in ulcerative colitis enteric
nerves has been found to be normal57 or
increased.54 For VIP the observations are even
more confusing. Whereas VIP concentration in
plasma of patients with active IBD is in-
creased,58 colon VIP content is reported to be
either decreased53,59,60 or increased.55,61 There
is no clear relation between VIP content and
disease activity.
Somatostatin
SMS was ￿rst extracted from ovine hypothala-
mus as an inhibitor of growth hormone se-
cretion.62 SMS is a peptide hormone. There are
two biologically active forms, consisting of 14
or 28 amino acids respectively. Most of the total
body SMS content is stored in the digestive
tract. About 75% is localized in gut and
pancreas.63,64 In stomach and pancreas SMS-14
prevails, and in the gut SMS-28.65 SMS contain-
ing cells are found in enteric mucosa, submu-
cosa and neural tissue.8 More than 90%of gut
SMS content is localized in the endocrine cells
of the mucosa, less than 10%in enteric nerves
of the muscular layer.66,67
Five types of SMS receptors have been dis-
covered, each with speci￿c binding character-
istics for SMS subtypes and different SMS
analogues.68 SMS receptors are found in upper
and lower parts of the normal digestive tract.66
SMS is an inhibitor of several key functions in
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￿uid absorption, intestinal and pancreas secre-
tion. SMS has effects on splanchnic blood ￿ow
and gastric and intestinal motility.66 SMS exerts
its inhibitory effects by diminishing intracellular
cAMP through G-protein activation. In addition,
SMS impedes cellular in￿ux of calcium. This
impediment results from a direct effect on
calcium channels and from increase of potas-
sium conductance with subsequent cellular
hyperpolarization.64 Circulating native SMS has
a short half-life time. Long-acting analogues like
the decapeptide octreotide have been devel-
oped69 and SMS analogues have been used to
treat intractable diarrhoea, bleeding from oeso-
phageal varices in portal hypertension, dumping
syndrome and gastrointestinal ￿stulae. 70- 74
Radioactive labelled SMS analogues serve as
diagnostic tools in visualization of gastrointest-
inal neuroendocrine tumours.75
Immunomodulatory Effects of
Somatostatin
Studies on the immunomodulatory effects of
SMS show several effects on T - and B-lympho-
cytes and macrophages. SMS receptors exist in
spleen, liver, thymus and gastrointestinal lymph-
oid tissue, as well as on various immuno-
cytes.12,15,76 Immunomodulating actions of SMS
were discovered as a result of its antagonizing
effects of proliferation of rat lymphocytes,
stimulated by hypothalamic extracts.77 SMS
inhibits responsiveness, immunoglobulin synth-
esis and proliferation of lymphocytes and gran-
ulocytes.15,45,46,78- 80 It reduces TNF release and
cellular toxicity of stimulated rat peritoneal
macrophages.30,81 Inhibitory effects depend on
local SMS concentration. Several in vitro studies
show inhibition of proliferation of lymphoid
cells at low SMS concentrations and stimulation
at high levels.46,77 In an experimental model of
intestinal in￿ammation with Schistosoma m an-
soni, SMS as well as its analogue octreotide
decrease T -cell interferon production signi￿c-
antly.82
Some studies report immunostimulating ef-
fects by SMS. T -cell proliferation is seen, also at
low SMS concentrations. 83,84 In rat peritoneal
macrophages SMS stimulates cytotoxic reactiv-
ity, when given in low concentrations.81 T -cell
activation in a hybridoma T -lymphocyte cell
line, measured by IL-2 release, is stimulated by
SMS in a dose-dependent way.17 However, IL-2
receptor expression is inhibited by SMS in
human intestinal lymphocytes.47,48
SMS controls in￿ammatory processes in in
vivo experimental models.Areduction of in￿am-
matory in￿ltrate and a diminished TNFaproduc-
tion occurs when SMS analogues are applied to
animals in which carrageen-induced skin in￿am-
mation is established.85 In this experiment
intense SMS immunostaining was seen on leuko-
cytes at peri-in￿ammatory sites. SMS reduces
in￿ammation in experimental arthritis and ileal
obstruction.86,87 Similar bene￿cial effects on
intestinal and colonic in￿ammation emerge from
clinical observations in Crohn’s disease and gold-
induced enteritis.88,89 SMS is able to reduce SP
mediated in￿ammation induced by intestinal
infection with Trichinella spiralis90 and SP
enhanced neutrophil chemotaxis.43
Somatostatin in IBD
No systematic in vivo or in vitro studies on
effects of SMS in IBD are available at present.
Support for SMS induced immunomodulation in
IBD is indirect and derived from morphological
and biochemical analyses of intestinal and blood
specimens from IBDpatients. From several stud-
ies a correlation between SMS activity and
presence and intestinal in￿ammation emerges.
When measured in serum total body SMS
release shows a circadian rhythm.91,92 In active
ulcerative colitis a higher 24-hour amplitude,
higher average serum levels and a longer meal-
stimulated peak level are observed.91,93 As the
serum concentration is only a faint mirror of
the mucosal events, the impact of increased
secretion of SMS is obscure. Same response
patterns are seen in patients with duodenal
ulcer or irritable bowel syndrome.93
SMScontaining cells and submucosal ganglion
cells in surgical specimen from IBDpatients can
be visualized by immunohistochemical staining
and quanti￿ed by counting the SMS containing
cells per cm. Mucosal SMS content can be
assessed by radioimmunoassay of homogenized
biopsy specimen. In normal colon mucosa, SMS
containing endocrine cells show the highest
density in the distal parts. In active IBD this
distinct difference disappears. Studies prior to
the discovery of SMS showed a decrease of
neuroendocrine enterochromaf￿n cells in dis-
eased rectum of ulcerative colitis patients.94,95
In ulcerative colitis there is an actual decrease
in SMS containing cells, especially in the distal
part of the colon. 96- 99 Although these changes
may be secondary to in￿ammatory damage to
mucosal SMS containing cells, this is refuted by
the fact that other mucosal neuropeptides like
SP show increased levels in these cases.98 SMS
containing submucosal ganglion cells are evenly
distributed along the colon in normals and IBD
patients, but the number of these cells is
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cultures from patients with active ulcerative
colitis, decreased SMS generation is observed.
This loss of SMS production correlates with
disease activity. 100
In Crohn’s disease the loss of SMS containing
colonic cells is less evident. A tendency towards
decrease of SMS positive cells with increasing
disease activity has been reported.97 No differ-
ence of SMS content is seen in mucosa or
normal ileum and terminal ileitis.98 Mucosal
biopsies from in￿amed jejunum in Crohn’s
disease show normal levels of SMS, but soluable
SMS is increased. 101 This may re￿ect instability
of SMS storage granules due to in￿ammation.
Several arguments for SMS involvement in
mucosal in￿ammation emerge from scinti-
graphic studies. An increased density of SMS
receptors is found in areas of granulomatous
in￿ammation like tuberculosis, sarcoidosis and
Wegener’s granulomatosus. 102- 104 From SMS re-
ceptor measurements in granulomas of murine
intestinal Schistosoma mansoni infestation
emerge the same results.82
High-af￿nity SMS receptors are found in
normal jejunum, ileum and colon. 105 Apart from
presence in colon mucosa and nerve plexus,
SMS receptors are found in the germinal centres
of colonic lymph follicles. SMS receptors are
seen in gut-associated lymphatic tissue, like
palatine tonsils, Peyer’s patches, vermicular
appendix and isolated lymphatic follicles in the
colon106 and SMS is isolated from nervous tissue
in Peyer’s patches. 107 The precise function of
SMS in this gut-associated lymphoid tissue has
not yet been settled. High receptor density is
seen in the luminal parts of secondary lymph
follicles, but they are absent from the corona of
B-lymphoid cells. Lymphoid aggregates without
a germinal centre do not show receptor
activity.106 Interaction of SMS and lymphocytes
from these germinal centres is reasonable. As
these receptors have high af￿nity for SMS, a
speci￿c immunomodulatory role of SMS is
anticipated. Other indications for a direct in￿u-
ence of SMS on intestinal immunocytes can be
derived from electron microscopic studies of
the gut wall. SMS containing enteric nerve
￿bres are present in a very high density near
intestinal lymph follicles, coming close to folli-
cular lymphocytes. 107
Inhibitory effects of SMS on vascular cell
proliferation have been described.108 Expression
of high af￿nity SMS receptors is seen in intra-
mural veins of in￿amed intestinal mucosa in
IBD or peri-in￿ammatory veins in rheumatoid
arthritis. 109,110 No difference is seen in SMS
receptor content of normal and in￿amed tissue
in mucosa, nerve plexus or lymphatic follicles.
Precise cellular localization of the SMSreceptors
is not possible from autoradiography, due to
insuf￿cient resolution of this visual technique.
Histologically these receptor positive veins are
normal, but the surrounding tissue often is
in￿ltrated by leukocytes and receptor positivity
is correlated with IBD activity.109 However,
expression of SMS receptors in vessel walls
could be a nonspeci￿c response to in￿amma-
tion as this phenomenon is also seen in
peritumoral tissues in resected SMS receptor
negative colon adenocarcinoma and other malig-
nancies. 111,112
In animal experimental models of in￿amma-
tory bowel disease there are several suggestions
of a role of SMS in the in￿ammatory mucosal
responses. In murine experimental colitis SMS
prevents mucosal damage effectively, especially
when given before the introduction of the
toxin.113 Parallel to decrease of mucosal lesions
a decrease of in￿ammatory mediators such as
leukotriene B4 and platelet activating factor is
seen.
Interleukin-2 receptor expression and DNA
synthesis in intestinal lamina propria lympho-
cytes (LPL) is reduced by SMS.44,47,48 Prolifera-
tion of Peyer’s patch derived lymphocytes is
inhibited by SMS. Inhibitory effects of SMS on
lymphocytic proliferation are more pronounced
in intestinal derived T -cells than in splenic
lymphocytes.114 Af￿nity of lamina propria lym-
phocytes for SMS-binding was found to be 1000
times higher than peripheral blood lymphocytes
in one study.48
However, con￿icting results emerge from a
study in which effects on human peripheral
blood lymphocytes and intestinal LPL were
compared. The effects of SMS on intestinal LPL
were minimal. Although both lymphoid cells
expressed high af￿nity SMS receptors, intestinal
lymphoid proliferation was poorly inhibited by
SMS. Immunoglobulin synthesis was affected in
a dose-related way in both peripheral and
intestinal lymphocytes.48 The fact that these
results run counter to earlier reported data, may
be due to species differences and the lack of
SMS receptor subtyping.
Intestinal granulomas induced by Schisto-
soma m ansoni are smaller in the presence of
SMS. Their output of interferon c and immuno-
globulin is diminished by SMS. As these same
granulomas are also capable of producing SMS,
this suggests a local immunoregulatory role for
SMS.19,82,115 This is supported by the interesting
observation that intra-epithelial lymphoid cells
can stimulate isolated intestinal epithelium to
produce SMS.116
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From morphological studies it is clear that
neuropeptides are probably involved in the
control of the intestinal immune system. Im-
mune stimulatory and inhibitory effects emerge
from various in vitro studies and from sparse in
vivo experiments. SMS has been shown to
inhibit immunological processes at various sites
following different stimuli. As SMS receptors
show a high density in the gastrointestinal
associated lymphoid tissue and in in￿ammatory
granulomas in murine Schistosom a mansoni
infestation, it seems likely that SMS and its
receptors play a role in immunological events of
the digestive tract. Mucosal SMS content is
reduced in active IBD. The bene￿cial effects of
SMS and SMS analogues on experimental in￿am-
mation of skin, joints and intestine and the few
reports on open studies in patients with IBD
suggest that SMS and SMS analogues could
possibly be bene￿cial in IBD and should stimu-
late further clinical studies.
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